Type 5 metabotropic glutamate receptors (mGluR5) activate protein kinase C (PKC) via coupling to G aq/11 protein signaling. We have previously demonstrated that the epsilon isoform of PKC (PKCE) is a critical downstream target of mGluR5 in regulating behavioral and biochemical responses to alcohol. Recent evidence suggests that PKC-mediated phosphorylation of mGluR5 can lead to receptor desensitization and internalization. We therefore sought to examine the specific involvement of PKCE in the regulation of mGluR5 surface expression in the nucleus accumbens (NAc), a key regulator of alcoholassociated behaviors. Coronal brain sections from male Wistar rats were analyzed for either colocalization of mGluR5 and PKCE via immunohistochemistry or changes in mGluR5 surface expression and PKCE phosphorylation following local application of PKCE translocation activator or inhibitor peptides and/or an orthosteric mGluR5 agonist. We observed colocalization of mGluR5 and PKCE in the NAc. We also showed that intra-NAc infusion of the PKCE translocation inhibitor EV1-2 increased mGluR5 surface expression under baseline conditions. Stimulation of mGluR5 with an orthosteric agonist DHPG, dose dependently increased ERK1/2 and PKCE phosphorylation as well as mGluR5 internalization in acute NAc slices. Finally, we observed that activation of PKCE translocation with Tat-WERACK peptide mediates agonist-independent mGluR5 internalization, whereas PKCE translocation inhibitor EV1-2 prevents agonist-dependent internalization of mGluR5 in NAc slice preparations. These findings suggest that the subcellular localization of mGluR5 in the NAc is regulated by PKCE under basal and stimulation conditions, which may influence the role of mGluR5-PKCE signaling in alcohol-related behaviors. V C 2016 Wiley Periodicals, Inc.
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Key words: acute brain slices; surface biotinylation; membrane trafficking; Tat peptide; phosphorylation; ERK1/2 Metabotropic glutamate receptors, including the type 5 receptor (mGluR5), modulate neurotransmission at the majority of excitatory synapses in the brain. mGluR5 are coupled via G aq/11 proteins to phospholipase C-and diacylglycerol-mediated cellular signaling, release of intracellular calcium and activation of a number of protein kinases (Niswender and Conn, 2010) . One of the key kinases activated by mGluR5 is protein kinase C (PKC; Abe et al., 1992; Pin et al., 1994) . Up to 12 PKC isoforms have been identified to date in mammals, suggesting a diverse array of functions. PKC isoforms are typically grouped into four subfamilies, conventional (a, bI, bII, and g), novel (d, E, h, u) , atypical (f, k/i), and PKC-related kinases1-3, based on their structural features and sensitivity to regulatory effects of second messengers Ca 21 and diacylglycerol (Newton, 2010; Rosse et al., 2010) . In this regard, PKCE activation is dependent on the availability of diacylglycerol generated downstream of G aq/11 -coupled GPCRs, including mGluR1/5 (Newton and Messing, 2010) . Upon activation, PKCE is redistributed to various cellular compartments, including the cell membrane, in a process called SIGNIFICANCE This study shows that the epsilon isoform of protein kinase C (PKCE), an enzyme that regulates alcohol sensitivity and intake, also regulates the surface expression of the type 5 metabotropic glutamate receptor (mGluR5) under baseline and activated conditions. This was observed in the nucleus accumbens, a key brain region involved in reward and motivation. These findings establish bidirectional activity between mGluR5 and PKCE, which may lead to new insights on how these signaling pathways regulate alcohol-related behaviors as well as other aspects of substance abuse and addiction. translocation. It is believed that translocation is important for regulation of enzyme activity and substrate specificity, and translocation of PKC isoforms is mediated by isozyme-specific anchoring proteins such the receptor for activated C kinase (RACK) protein family (Schechtman and Mochly-Rosen, 2001; Schechtman et al., 2004) . Phosphorylation is another important mechanism that regulates PKCE activity (Cenni et al., 2002) . PKCE contains several phosphorylation sites that are thought to play critical role in priming kinase activity or delaying kinase degradation (Wang et al., 2016) . Previous research shows that PKCE activity can play an important role in cardioprotection during heart failure (Ferreira et al., 2011) and progression of various types of tumors (Jain and Basu, 2014) and in the behavioral response to alcohol (Hodge et al., 1999; Zeidman et al., 2002; Shirai et al., 2008; Migues et al., 2010) and, more recently, cocaine .
With regard specifically to alcohol, it has been shown that brief exposure of PKCE-expressing cell lines to alcohol causes enzyme translocation from perinuclear regions to the cytoplasm (Gordon et al., 1997) . In animals, binge alcohol drinking elevates phospho-Ser729-PKCE levels in both the NAc and the central nucleus of the amygdala in mice (Cozzoli et al., 2015) . Cozzoli et al. further demonstrated that inhibition of PKCE translocation within both brain regions reduced binge alcohol consumption in a manner dependent on intact function of mGluR1/5. Likewise, a previous study by our group demonstrated that PKCE is a downstream signaling target of mGluR5 that mediates the ability of mGluR5 antagonists to reduce voluntary alcohol intake when administered systemically (Olive et al., 2005) or into the nucleus accumbens (NAc; Gass and Olive, 2009 ). These findings suggest that ventral striatal mGluR5 receptors are coupled to PKCE and that in turn activity of PKCE is critical for mGluR5 regulation of alcohol-related behaviors. However, the nature and the cellular mechanisms of PKCE-dependent regulation of mGluR5 remain unclear.
In general, activation of PKC results in phosphorylation a number of cellular substrates, including mGluR1/ 5 (Mao et al., 2008) . PKC-mediated phosphorylation of mGluR1/5 can then lead to receptor desensitization and internalization (Gereau and Heinemann, 1998; Lee et al., 2008; Ko et al., 2012) . Decreased surface expression of mGluR5 in the striatum following a prolonged withdrawal from cocaine self-administration (Knackstedt et al., 2014) coincides with increased phosphorylation of PKCE in the same tissue (Schwendt and Olive, 2012) . To investigate the relationship between PKCE activation and mGluR5 surface expression, the present study sought to determine whether 1) mGluR5 and PKCE colocalize in the rat NAc, 2) whether stimulation of mGluR5 in vivo increases PKCE activation as measured by phosphorylation of PKCE Ser729 in this region, and 3) whether activation or inhibition of PKCE translocation alters mGluR5 surface expression in the NAc. Abnormal function of mGluR5 has been implicated in the pathophysiology of many neurological and psychiatric disorders, including anxiety, schizophrenia, fragile X mental retardation syndrome and drug addiction, so understanding and manipulating mGluR5-PKCE functional interactions may be used in the development of novel neurobiologically based therapies (Olive, 2009 ).
MATERIALS AND METHODS

Animals
Adult male Wistar rats (Charles River Laboratories, Raleigh, NC) weighing 275-300 g were singly housed in a temperature-and humidity-controlled vivarium on a reversed 12-hr light/dark cycle with food and water available ad libitum. All animal procedures used in this study were performed in accordance with the NIH Guide for the care and use of laboratory animals and approved by an Institutional Animal Care and Use Committee.
Drugs and Tat Peptides
(RS)-3,5-dihydroxyphenylglycine (DHPG) was purchased from Abcam Biochemicals (Cambridge, MA) and dissolved in artificial cerebrospinal fluid (ACSF; in mM: 125 NaCl, 1 CaCl 2 , 2.5 KCl, 4 MgCl 2 , 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 0.4 ascorbic acid, and 10 D-glucose). Peptides were custom synthesized by AnaSpec (Fremont, CA) and dissolved in ACSF at concentrations based on results of previous studies (Liron et al., 2007; Gass and Olive, 2009 ). To facilitate cell permeability, peptides were modified at their Nterminus by attaching either myristoyl acid (CH 3 (CH 2 ) 12 COOH) or Tat peptide sequence YGRKKRRQRRR (Tat [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ). Peptides used here were the PKCE translocation activator HDAPIGYD (Tat-WERACK), the PKCE translocation inhibitor EAVSLKPTT (Tat-EV1-2), and scrambled control peptides (Tat-sc). Peptide inhibiting PKCE translocation was also used in its myristyolated form (Myr-EV1-2). Concentrations of DHPG and PKCE peptides used in this study were based on previously published information (Mao et al., 2005; Bajo et al., 2008; Tronson et al., 2010; Wang et al., 2013) .
Immunohistochemistry (Experiment 1)
Rats were anesthetized with sodium pentobarbital (100 mg/kg) and transcardially perfused with phosphatebuffered saline (PBS) followed by 4% w/v paraformaldehyde (pH 7.4) in PBS. Brains were then removed, postfixed overnight at 4 C, and cryoprotected in a 30% w/v sucrose/PBS solution for at least 48 hr at 4 C. Next, 40-lm-thick sections were cut on a cryostat, and free-floating sections were then preblocked with PBS containing 0.1% Tween 20 (PBST) and 5% v/v normal donkey serum for 2 hr. Sections were then incubated with rabbit anti-mGluR5 (Neuromics, Edina, MN) and mouse anti-PKCE (BD Transduction Laboratories, San Jose, CA) primary antisera overnight at 4 C under gentle agitation. On the following day, sections were washed in PBST and incubated with AlexaFluor488-conjugated donkey anti-mouse IgG (1:500) and AlexaFluor568-conjugated donkey anti-rabbit IgG (1:500) secondary antisera (Jackson Immunoresearch, West Grove, PA) for 4 hr at room temperature. Finally, sections were washed, mounted onto microscope slides with mounting media containing an antifade reagent, coverslipped, sealed, and stored in darkness. Immunoreactivity in the NAc ws visualized on a Leica SP5 confocal laser scanning microscope equipped with a krypton/argon laser at 3 10-40. Images were obtained at a 400 Hz scan speed at an eight-bit pixel resolution of 1,024 3 1,024. AlexaFluor488 was excited at 488 nm with an emission filter of range 495-520 nm, and AlexaFluor568 was excited at 568 nm with an emission filter of range 575-620 nm. Pixels from AlexaFluor488 wavelengths were assigned a green color, pixels from AlexaFluor594 wavelengths were assigned a red color, and overlapping pixels were assigned a yellow color. For assessment of the degree of colocalization of mGluR5 and PKCE, a total of six images each of the NAc core and shell subregions were obtained, and the number of colocalized cells was divided by the total number of mGluR5-positive cells to yield a percentage colocalization value. All primary antibodies used in this study are described in detail in Table I .
Stereotaxic Surgery and Intracranial Peptide Administration (Experiment 2)
Rats were anesthetized with ketamine-HCl (87.5 mg/kg, IM) and xylazine (5 mg/kg, IM). Ketorolac (3 mg/kg, IP) was administered preoperatively to provide analgesia. Animals were then placed into a small-animal stereotaxic instrument (Stoelting, Wood Dale, IL), and guide cannulas were implanted and secured with dental cement. Cannulas (20 gauge; Plastics One, Roanoke, VA) were implanted 2 mm above the infusion target according to the following coordinates: NAc 1 1.8 mm AP, 6 2.5 mm ML 6 angle, -7.0 mm DV relative to bregma according to (Paxinos and Watson, 2007) . Animals were allowed to recover for 5 days prior to the intracranial infusions of myristoylated peptides. For the infusion, two 33-gauge microinjectors that extended 2 mm beyond the tip of the guide cannula were bilaterally inserted into the NAc. Scrambled myristoylated control peptide) or Myr-EV1-2 peptides (5 pmol) was infused at a rate of 0.5 ml/min in a total volume of 0.5 ml/side (NAc) using an infusion pump (Harvard Apparatus, Holliston, MA). After the infusion had been completed, the microinjectors were left in place for an additional 1 min to allow for diffusion of peptides. Animal were sacrificed 20 min following the infusion, and acute NAc slices were prepared as described below.
Slice Preparation and Treatment (Experiments 3 and 4)
After rapid decapitation, rat brains were removed and briefly chilled in ice-cold ACSF oxygenated with 95% O 2 /5% CO 2 . Next, 2-mm-thick coronal slices containing the NAc were prepared with the rat brain matrix (ASI instruments, Warren, MI). The NAc tissue was then bilaterally dissected with a 2-mm micropunch (Harris-Unicore; Ted Pella, Redding, CA) as illustrated in Figure 2A and cut into 250-lm slices with a McIlwain Tissue Chopper (Stoelting). Acute NAc slices were equilibrated for 1 hr at 22 C in oxygenated ACSF. After equilibration, slices were incubated with Tat peptides (5 mM) for 45 min at 37 C in oxygenated ACSF (for details see Ster et al., 2009) . Alternatively, after 15 min incubation with Tat peptides, 100 mM DHPG was added to subsets of slices for an additional 30 min. Immediately after incubation with peptides or DHPG, slices were washed with ice-cold ACSF and subjected to surface biotinylation as described below. Incubation times and conditions were based on the literature (Choe and Wang, 2001; Lee at el., 2008; Jin et al., 2013) . In addition to slice preparation as described above, in experiment 3 the presence of peptide infusion site in the dissected NAc tissue was verified as follows: first, 2 mm coronal slice had to contain the signs of microinjection point of entry into the brain, and, second, the presence of cannulea tracks in NAc slices was visually confirmed.
Surface Biotinylation (Experiments 2-4)
Surface biotinylation was conducted as described in our previous studies (Knackstedt et al., 2014; Knackstedt and Schwendt, 2016 ) with a few modifications. Briefly, NAc slices were biotinylated with 1 mg/ml EZ Link NHS-SS-Biotin/ ACSF (Thermo Fisher Scientific, Rockford, IL) for 1 hr at 4 C. Next, the biotinylation reaction was quenched with a 100 mM glycine/ACSF buffer. Biotinylated slices were homogenized in a lysis buffer (25 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with protease and phosphatase inhibitors. After incubation for 1 hr at 4 C, insoluble debris was removed by centrifugation. An equal aliquot of precleared solubilized total protein fraction (T) was saved and frozen at -80 C. Biotinylated proteins were captured by incubating with Neutravidin agarose beads (Thermo Fisher Scientific) overnight at 4 C. After nonbiotinylation, intracellular (I) proteins were removed, bound biotinylated surface (S) proteins were recovered from the beads with elution buffer (62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, and 50 mM dithiothreitol, pH 6.8) and incubation at 95 C for 10 min. Protein concentration in total, I, and S fractions was determined by using BCA assay (Thermo Fisher Scientific), and proteins of interest were analyzed by immunoblotting as described below.
Immunoblotting (Experiments 2-4)
Equal aliquots from each fraction separated by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 1 hr in 5% milk/Tris-buffered saline and probed overnight at 4 C with the following primary antibodies diluted in 5% milk/Tris-buffered saline containing 0.1% Tween-20: calnexin (Enzo Life Sciences, Farmingdale, NY); syntaxin1a (Abcam, Cambridge, MA); mGluR5, PKCE, and phospho-(Ser729)-PKCE (all from Millipore, Billerica, MA); and ERK1/ 2 and phospho-ERK1/2 (both from Cell Signaling Technology, Danvers, MA). After incubation with an appropriate horseradish peroxidase-conjugated secondary antiserum (Jackson Immunoresearch), immunoreactive bands on the membranes were detected by ECL 1 chemiluminescence reagents on an Xray film (GE Healthcare, Piscataway, NJ). Subsequently, blots were stripped and reprobed with calnexin and syntaxin-1a antibodies to monitor biotinylation of intracellular proteins and to normalize for unequal loading and/or transfer of proteins. The integrated band density of each protein sample was measured in NIH ImageJ version 1.32j (RRID: SCR_003070). All primary antibodies used in this study are described in detail in Table I .
Statistical Analysis
Immunoblotting data, represented by integrated density of individual protein bands, were normalized to the density of calnexin or syntaxin-1a immunoreactivity within the same sample. Differences between treatment groups were analyzed by Student's t-test or by one-way ANOVA followed by multiple comparisons vs. control group (Bonferroni test). For immunohistochemical colocalization data, a single value for each NAc subregion in each tissue section was obtained and averaged across all sections, and data were analyzed via Student's t-test. For all statistical analyses used, the alpha level was set at 0.05. Sigma Plot version 10 (RRID:SCR_003210; Systat Software, San Jose, CA) was used to analyze all data.
RESULTS
Experiment 1: Colocalization of mGluR5 and PKCE in the NAc
Immunoreactivity for both mGluR5 and PKCE were highly cytoplasmic within cell bodies in the NAc, with occasional immunoreactivity in singular processes extended from the cell soma (Fig. 1) . PKCE immunoreactivity was found to be colocalized with that of mGluR5 in approximately one-third of mGluR5-positive cells (NAc core 32.06% 6 3.91%, NAc shell 32.24% 6 1.37%), and there were no significant differences in the percentage of cells demonstrating colocalization of these two antigens (t[6] 5 -0.04, P > 0.05).
Experiment 2: Inhibition of PKCE Translocation
In Vivo Increases Surface Expression of mGluR5 in the NAc mGluR5 protein was detected in both surface and intracellular fractions obtained by surface biotinylation of acute NAc slices ( Fig. 2A) . Under the mild reducing conditions used in this study, the dimer was the predominant form of mGluR5 detected. The mGluR5 dimer is thought to represent mature, functional form of mGluR5 (Brock et al., 2007) , so in the remainder of this study (experiments 2-4) only the dimeric form of mGluR5 was analyzed. The presence of the membrane protein syntaxin-1a in the surface fraction and limited or no presence of known intracellular proteins (PKCE and calnexin) in the same fraction demonstrated that biotinylation selectively labeled cell surface proteins ( Fig. 2A) . The presence Fig. 2 . Intra-NAc infusion of the PKCE translocation inhibitor Myr-EV1-2 increases mGluR5 surface expression under baseline (nonstimulated) conditions. A: Rat brain atlas coordinates (adapted from Paxinos and Watson, 2007) depicting the site of intra-NAc infusions in relation to the site of tissue dissection used for slice preparation. Representative immunoblots show the distribution of mGluR5 and other proteins total (T), surface (S), and intracellular (I) fraction as detected by surface biotinylation assay in acute NAc slices. The presence of the membrane protein syntaxin-1a in the surface fraction and limited or no presence of known intracellular proteins (PKCE and calnexin) in the same fraction demonstrates that biotin selectively labeled surface proteins. B: Intra-NAc application of the PKCE translocation inhibitor Myr-EV1-2 (5 pmol/ml) increased surface mGluR5 levels left panel, and decreased intracellular mGluR5 levels (B, right) in acute NAc slices. No changes in total mGluR5 levels were detected. Representative immunoblots (top) show the distribution of mGluR5 in total (T), surface (S), and intracellular (I) fraction as detected by surface biotinylation assay in acute NAc slices. n 5 4 per group; *P < 0.05 vs. scrambled control peptide. NAc, nucleus accumbens; stx1a, syntaxin1a; (d), mGluR5 dimer; (m), mGluR5 monomer. of syntaxin-1a in both surface membrane and intracellular fractions corresponds with its known role in presynaptic exo-and endocytosis (see, e.g., Wu et al., 1999; Yu et al., 2006) . Microinfusion of the myristoylated PKCE translocation inhibitor peptide Myr-EV1-2 (5 pmol/ml) into the NAc resulted in increased surface expression of mGluR5 in NAc slices compared with local application of a scrambled control Myr peptide ( Fig. 2B ; t[6] 5 2.67, P < 0.05). This increase in mGluR5 surface expression was accompanied by reduced levels of intracellular mGluR5 ( Fig. 2C ; t[6] 5 2.79, P < 0.05) without a change in total receptor levels (data not shown), suggesting that inhibition of PKCE translocation promotes insertion of intracellular mGluR5 receptors into the membrane under basal (unstimulated) conditions.
Experiment 3: Activation of mGluR5 Dose Dependently Increases mGluR5 Internalization as Well as ERK1/2 and PKCE Phosphorylation in Acute NAc slices
Incubation of NAc slices with the group I mGluR agonist DHPG dose dependently altered the surface expression of mGluR5 as well as the phosphorylation state of two kinases, ERK1/2 and PKCE, known to be phosphorylated in response to mGluR5 activation (Choe and Wang, 2001; Olive et al., 2005) . With regard to mGluR5 surface expression, one-way ANOVA revealed a main effect of DHPG treatment (F 2,10 5 4.67, P < 0.05). Post hoc analysis revealed that mGluR5 surface expression was reduced in NAc slices treated with 100 lM DHPG compared with vehicle-treated slices ( Fig. 3A ; P < 0.05). There was also a main effect of DHPG treatment on phosphorylation of ERK1/2 in the NAc (F 2,10 5 17.96, P < 0.01). Treatment with 100 lM (but not 10 lM) DHPG increased phosphorylation of ERK1/2 in the NAc slices compared with vehicle-treated slices ( Fig. 3B ; P < 0.01). One-way ANOVA analysis revealed a main effect of DHPG treatment on phosphorylation of PKCE at Ser729 (F 2,10 5 7.22, P < 0.05). Again, increased phosphorylation was observed only in the NAc slices treated with the highest (100 lM) concentration of DHPG ( Fig. 3C ; P < 0.05).
Experiment 4a: PKCE Activation Mediates Agonist-Independent and Agonist-Dependent Internalization of mGluR5 in Acute NAc Slices
In this experiment, the effects of the PKCE translocation inhibitor (Tat-EV1-2) or activator (Tat-wERACK) on surface trafficking of mGluR5 were studied in NAc slices under baseline conditions and following DHPG treatment. Under baseline conditions (no mGluR5 agonist present), one-way ANOVA revealed a main effect of Tat peptides on surface (F 3,18 5 6.89, P < 0.01) and intracellular (F 3,18 5 6.83, P < 0.01) expression of mGluR5 receptors (Fig. 4A) . Post hoc analysis showed that there was a significant decrease in mGluR5 surface expression in NAc slices treated with Tat-wERACK compared with slices treated with nonfunctional scrambled Tat peptide (Tat-sc; P < 0.05). Furthermore, there was a significant increase in intracellular mGluR5 levels (P < 0.01 vs. Tat- sc), indicating internalization of mGluR5 in response to Tat-wERACK. There was no difference in mGluR5 surface or intracellular levels between ACSF and Tat-sc treatments. Next, the effects of Tat peptides on mGluR5 surface trafficking in the presence of an agonist (100 lM DHPG) were evaluated. One-way ANOVA revealed the significant effect of DHPG/Tat peptide treatment on surface (F 3,18 5 4.93, P < 0.05) and intracellular (F 3,18 5 8.39, P < 0.01) mGluR5 levels (Fig. 4B) . Post hoc analysis showed that DHPG alone increased internalization of mGluR5, as demonstrated by the decrease in surface mGluR5 levels (Tat-sc-DHPG vs. Tat-sc, P < 0.05) and simultaneous increase in intracellular mGluR5 levels (Tat-sc-DHPG vs. Tat-sc, P < 0.01). The effect of DHPG was prevented by pretreatment with Tat-EV1-2 peptide (Tat-sc 1 DHPG vs. Tat-EV1-2 1 DHPG; n.s.). Combined treatment with DHPG and Tat-wERACK also increased internalization of mGluR5 (decreased surface levels, P < 0.05; increased intracellular levels, P < 0.01), but the effect was not different from the effects of DHPG treatment alone (Tat-wERACK 1 DHPG vs. Tat-sc 1 DHPG, n.s.). Fig. 4 . PKCE activation mediates agonist-independent and agonistdependent internalization of mGluR5 in acute NAc slices. Top panels show representative immunoblot images of mGluR5 signal as detected in total lysate (T), surface (S), and intracellular (I) fractions prepared from acute NAc slices treated with 5 mM Tat-sc, Tat-EV1-2, and Tat-wERACK in combination with ACSF vehicle (A) or 100 mM DHPG (B). Center and bottom panels show quantitative analyses of surface and intracellular mGluR5 levels normalized to total mGluR5 levels in acute NAc, revealing that PKCE translocation activator WERACK promotes internalization of mGluR5 in acute NAc slices (A), whereas pretreatment with the PKCE translocation inhibitor Tat-EV1-2 prevents DHPG-dependent mGluR5 internalization (B). n 5 5-6 per group; *P < 0.05, **P < 0.01 vs. Tat-sc. (d), mGluR5 dimer.
Experiment 4b: Effects of PKCE Activation on Agonist-Dependent/-Independent Phosphorylation of ERK1/2 and PKCE in Acute NAc Slices Phosphorylation of ERK1/2 and PKCE was analyzed in total (T) NAc lysates obtained in Experiment 4a. Under baseline conditions (e.g., no mGluR5 agonist present), one-way ANOVA revealed a main effect of Tat peptides on phosphorylation of ERK1/2 (F 3,18 5 9.97, P < 0.01; Fig. 5A ). Post hoc analysis showed that there was a significant increase in phospho-ERK1/2 levels in NAc slices treated with Tat-wERACK compared with slices treated with nonfunctional Tat-sc (P < 0.01). There was no difference in phospho-ERK1/2 levels between ACSF-and Tat-sc-treated groups. Phosphorylation of Fig. 5 . PKCE activation and agonist-dependent/-independent phosphorylation of ERK1/2 and PKCE in acute NAc slices. Top panels show representative immunoblot images of phospho-(Thr202/ Tyr204)-ERK1/2 and phospho-(Ser729)-PKCE signal as detected in total lysate (T) prepared from acute NAc slices treated with 5 mM Tat-sc, Tat-EV1-2, and Tat-wERACK in combination with ACSF vehicle (A) or 100 mM DHPG (B). Center and bottom panels show quantitative analyses of phospho-ERK1/2, revealing that treatment of acute NAc slices with Tat-WERACK (A) or DHPG (B) increased phosphorylation of ERK1/2. Agonist-dependent ERK1/2 phosphorylation was not altered by Tat-EV1-2 or Tat-WERACK. DHPG also induced PKCE phosphorylation that was prevented by Tat-EV1-2 pretreatment (B). n 5 5-6 per group; *P < 0.05, **P < 0.01 vs Tat-sc. (d), mGluR5 dimer; pERK1/2, phospho-ERK1/2. PKCE was not altered in any of the treatment groups (F 3,18 5 0.74, n.s.; Fig. 5A ). Next, the effects of Tat peptides on ERK1/2 and PKCE phosphorylation were evaluated in the presence of an mGluR5 agonist (100 lM DHPG). One-way ANOVA revealed the significant effect of DHPG/Tat peptide treatment on phosphorylation of both ERK1/2 (F 3,18 5 11.69, P < 0.01) and PKCE (F 3,18 5 6.49, P < 0.01, Fig. 5B ). Post hoc analysis showed increased ERK1/2 phosphorylation in all samples treated with DHPG (regardless of Tat peptide treatment; Tat-sc 1 DHPG, P < 0.01; Tat-EV1-2 1 DHPG, P < 0.05; Tat-wERACK 1 DHPG, P < 0.01; all vs. Tat-sc). Furthermore, post hoc analysis of phospho-PKCE levels revealed increased phosphorylation of this kinase in samples treated with DHPG alone (Tat-sc-DHPG vs. Tat-sc, P < 0.05) or with combination DHPG and TatwERACK peptide (Tat-wERACK 1 DHPG vs. Tat-sc, P < 0.01). The effect of DHPG was prevented by pretreatment with Tat-EV1-2 peptide (Tat-sc 1 DHPG vs. Tat-EV1-2 1 DHPG, n.s.).
DISCUSSION
The present study demonstrates anatomical and functional interactions between mGluR5 and PKCE in the NAc. First, we show that both of these proteins colocalize in the same cell populations in this region, with no differences in the relative amount of colocalization between NAc subregions (shell or core). Although previous studies have shown that mGluR5 and PKCE are both highly expressed in the NAc (Saito et al., 1993; Shigemoto et al., 1993; Romano et al., 1995) , to our knowledge this is the first demonstration that these proteins are coexpressed by the same cell types (Fig. 1) . This finding was not surprising because PKC signaling is a known downstream target of mGluR5 via coupling to G q/11 proteins (Niswender and Conn, 2010) . We found that PKCE was expressed in approximately one-third of mGluR5-positive cells, suggesting that surface expression of mGluR5 in other cells of the NAc is potentially regulated by PKCE-independent mechanisms. Previous studies using neuronal tracing and in situ hybridization or immunohistochemical approaches have revealed that mGluR5 receptors are expressed in approximately 80% of striatal projection neurons (Lu et al., 2009 ), yet a significant percentage (65%) of cholinergic interneurons of the striatum also expresses mGluR5 (Tallaksen-Greene et al., 1998) . Future studies are needed to determine the neurochemical phenotype and projection targets of NAc neurons that coexpress mGluR5 and PKCE.
Previous evidence suggest that constitutive PKCE activity can be detected in rodent brain tissue (Bazzi and Nelsestuen, 1988; Olive et al., 2005; Bajo et al., 2008; Cozzoli et al., 2015) and that PKC-dependent phosphorylation of mGluR5 receptors is associated with their internalization (Lee et al., 2008) . Therefore, we examined whether inhibition of PKCE translocation, which is critical for its activation, increases surface expression of mGluR5 in the NAc (experiment 2). We found that microinfusion of the PKCE translocation inhibitory peptide (Myr-EV1-2) resulted in increased levels of surface mGluR5, concurrent with decreased intracellular levels of this protein. These results suggest that, under basal (nonstimulated) conditions, PKCE plays a role in maintaining an intracellular pool of mGluR5. Similar observations have been reported for regulation of dopamine, serotonin, and amino acid receptors and transporters by PKC and its RACK (Barnes, 2000; Lee et al., 2004; Steiner et al., 2008; Schmitt and Reith, 2010; Nissen-Meyer and Chaudhry, 2013) . Further studies are needed to determine whether other PKC isozymes in the NAc also regulate the subcellular localization of mGluR5 receptors.
In addition to regulation of mGluR5 trafficking by constitutive PKCE activity, we sought to determine whether pharmacological activation of mGluR5 receptors results in activation of PKCE and other known intracellular signaling targets of this receptor (experiment 3). Indeed, we observed that mGluR1/5 agonist DHPG dose dependently increased levels of phosphorylated PKCE at the Ser729 residue as well as phosphorylated forms of ERK1/2. These findings are consistent with those of prior studies that have established phospho-Ser729 PKCE as a marker of activation of this PKC isozyme (Parekh et al., 1999; Cenni et al., 2002) and ERK1/2 as a signaling target of mGluR5 (Thandi et al., 2002; Mao et al., 2005) . These findings are also consistent with our previous observations for the dorsal striatum, in which pharmacological activation of mGluR5 with the orthosteric agonist CHPG also increases phosphorylation of PKCE at Ser729 as well as other activation sites such as Thr566, but not other PKC isoforms (Olive et al., 2005) . In general, phosphorylation of PKCE at Ser729 site has been associated with changes in intracellular location of PKCE and priming of the kinase for activation. Some studies suggest that phospho-Ser729 PKCE is translocated from cytosol to the plasma membrane (e.g., Schonhoff et al., 2009 ), a process guided by RACK proteins (Fenton et al., 2009 ). Therefore, phosphorylation and translocation of PKCE to the membrane may bring activated PKCE to the proximity of mGluR5 receptors, where it can alter receptor trafficking via direct phosphorylation of this receptor (see Ko et al., 2012) .
Because mGluR5 surface expression may depend on both constitutive and inducible activity of PKCE, we next investigated PKCE-dependent regulation of mGluR5 subcellular localization under both baseline and pharmacologically induced activation conditions (experiment 4a). We observed that local application of the PKCE translocation activator WERACK promoted internalization of mGluR5 in acute NAc slices under nonstimulated conditions, as evidenced by increased intracellular protein and decreased surface levels, but had no effect on DHPG-stimulated receptor internalization. However, pretreatment with the PKCE translocation inhibitor Tat-EV1-2 prevented DHPG-dependent mGluR5 internalization. Thus, PKCE appears to regulate the subcellular localization of mGluR5 under both nonstimulated and stimulated conditions, consistent with prior reports for isozyme nonselective PKC activators and inhibitors (Gereau and Heinemann, 1998; Lee et al., 2008; Ko et al., 2012) . When comparing the effects peptide PKCE inhibitors on mGluR5 surface expression under nonstimulated conditions, we noted a discrepancy between the in vivo effects of Myr-EV1-2 (Fig. 2) and the ex vivo effects of Tat-EV1-2 (Fig. 4) . Specifically, although Myr-EV1-2 significantly increased mGluR5 surface levels, Tat-EV1-2 had a small but statistically nonsignificant increase. The observed efficacy of Myr-EV1-2 in vivo is in agreement with our previous study showing mGluR5-dependent effects of Myr-EV1-2 on alcohol reinforcement after its intra-NAc infusion (Gass and Olive, 2009) . Other studies have shown that administration of myristotylated inhibitory peptides can block the activity of various kinases, including PKC isoforms (Eichholtz et al., 1993; Zeidman et al., 2002; Migues et al., 2010) and also alter receptor trafficking (Migues et al., 2010) . However, peptide myristoylation also promotes membrane association, which may limit peptide diffusion various subcellular compartments (Nelson et al., 2007) . Therefore, in more recent studies, Tat conjugation is often preferred because it offers increased cell penetrance and distribution relative to myristoylation (Reissmann, 2014) . Therefore, the unexpected efficacy of myristoylated PKCE pseudosubstrate peptides (vs. Tat-conjugated peptides) on mGluR5 trafficking likely is not due to higher cellular penetration of Myr-EV1-2. We speculate that other factors specific to in vivo conditions, such as higher rates of internalization or higher baseline activity of PKCE, are contributing to this phenomenon. Future studies are therefore needed to compare directly the effects of myristoylation and Tat conjugation on mGluR trafficking in vivo and ex vivo.
In addition to surface trafficking (experiment 4a), phosphorylation of ERK1/2 and PKCE was analyzed in total NAc lysates (experiment 4b). With regard to ERK1/2, immunoblot analysis revealed both mGluR5 agonist-independent and agonist-dependent cellular mechanisms that contribute to ERK1/2 phosphorylation in the NAc. Increases in phospho-ERK1/2 levels were observed both after administration of the PKCE translocation activator WERACK (no agonist present, Fig. 5A ) and in all samples treated with DHPG (Fig. 5B) . Although the ability of DHPG to induce ERK1/2 phosphorylation is in agreement with our other experiments (experiment 3, Fig. 3B ) and with previously published studies (e.g., Mao et al., 2005) , a direct link between PKCE activity/translocation and ERK1/2 phosphorylation in the brain has not been previously demonstrated. In one study, upregulation of phospho-ERK1/2 was observed in neonatal myocytes overexpressing PKCE (Heidkamp et al., 2011) . DHPGinduced ERK1/2 phosphorylation was not altered by pretreatment with the PKCE translocation inhibitor EV1-2. This is not surprising because activation of several different signaling pathways downstream from mGluR5 can lead to phosphorylation of ERK1/2 after DHPG treatment (e.g., CaMKII; Choe and Wang, 2001) . In contrast, inhibition of PKCE translocation partially reversed DHPG effects on PKCE phosphorylation, suggesting that translocation is important for full activation and phosphorylation of PKCE. It should be noted, however, that downstream signaling of another group I mGluR (mGluR1) can also be regulated by PKCE, at least in tumor tissue (Marin et al., 2006) . In the NAc, mGluR1 is expressed at much lower levels than mGluR5 (Testa et al., 1994; Kerner et al., 1997; Tallaksen-Greene et al., 1998) , and therefore mGluR1 was not investigated in the current study.
In summary, our findings indicate that mGluR5 and PKCE are colocalized in subpopulations of cells in both the NAc core and the NAc shell and that the subcellular localization of mGluR5 in the NAc is regulated by PKCE under basal and stimulated conditions. It is important for future studies to explore potential interactions between mGluR5 and PKCE in other addiction-related brain regions such as the amygdala or prefrontal cortex, for which it has been demonstrated that either of these proteins regulates drug-seeking and related behaviors (Lesscher et al., 2009; Cozzoli et al., 2016; Miller et al., 2016) . Given the known role of mGluR5 signaling in the NAc in alcohol-and other drug-related behaviors such as drug intake and relapse, these findings pose important questions for potential targeting of mGluR5-PKCE signaling in the treatment of substance use disorders.
